Can magnetic resonance imaging enhance the assessment of potential new treatments for cognitive impairment in mood disorders? A systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task Force

Imagem de Miniatura
Arquivos
art_MISKOWIAK_Can_magnetic_resonance_imaging_enhance_the_assessment_of_2022.PDF (903.66 KB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2022
Editora
WILEY
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Métricas da Revista
JCR
SJR
Autores
MISKOWIAK, Kamilla W.
YALIN, Nefize
SEEBERG, Ida
BURDICK, Katherine E.
BALANZA-MARTINEZ, Vicent
BONNIN, Caterina del Mar
BOWIE, Christopher R.
CARVALHO, Andre F.
DOLS, Annemieke
DOUGLAS, Katie
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
BIPOLAR DISORDERS, v.24, n.6, p.615-636, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Developing treatments for cognitive impairment is key to improving the functioning of people with mood disorders. Neuroimaging may assist in identifying brain-based efficacy markers. This systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task Force examines the evidence from neuroimaging studies of pro-cognitive interventions. Methods We included magnetic resonance imaging (MRI) studies of candidate interventions in people with mood disorders or healthy individuals, following the procedures of the Preferred Reporting Items for Systematic reviews and Meta-Analysis 2020 statement. Searches were conducted on PubMed/MEDLINE, PsycInfo, EMBASE, Cochrane Library, and from inception to 30th April 2021. Two independent authors reviewed the studies using the National Heart, Lung, Blood Institutes of Health Quality Assessment Tool for Controlled Intervention Studies and the quality of neuroimaging methodology assessment checklist. Results We identified 26 studies (N = 702). Six investigated cognitive remediation or pharmacological treatments in mood disorders (N = 190). In healthy individuals, 14 studies investigated pharmacological interventions (N = 319), 2 cognitive training (N = 73) and 4 neuromodulatory treatments (N = 120). Methodologies were mostly rated as 'fair'. 77% of studies investigated effects with task-based fMRI. Findings varied but most consistently involved treatment-associated cognitive control network (CCN) activity increases with cognitive improvements, or CCN activity decreases with no cognitive change, and increased functional connectivity. In mood disorders, treatment-related default mode network suppression occurred. Conclusions Modulation of CCN and DMN activity is a putative efficacy biomarker. Methodological recommendations are to pre-declare intended analyses and use task-based fMRI, paradigms probing the CCN, longitudinal assessments, mock scanning, and out-of-scanner tests.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/50652
Referências
  1. Alda M, 2017, BRIT J PSYCHIAT, V210, P54, DOI 10.1192/bjp.bp.115.173930
  2. Alonso-Lana S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158867
  3. [Anonymous], 2017, FDA CRITICAL PATH IN
  4. Apud JA, 2007, NEUROPSYCHOPHARMACOL, V32, P1011, DOI 10.1038/sj.npp.1301227
  5. Balice-Gordon R, 2020, INT J NEUROPSYCHOPH, V23, P287, DOI 10.1093/ijnp/pyaa007
  6. Barbey AK, 2018, TRENDS COGN SCI, V22, P8, DOI 10.1016/j.tics.2017.10.001
  7. Bartels C, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-118
  8. Batalla A, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.618184
  9. Bilek E, 2013, J NEUROSCI, V33, P7050, DOI 10.1523/JNEUROSCI.3081-12.2013
  10. Bloomfield MAP, 2020, J PSYCHOPHARMACOL, V34, P981, DOI 10.1177/0269881120936419
  11. Borsook D, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.43
  12. Brown ES, 2013, J AFFECT DISORDERS, V150, P551, DOI 10.1016/j.jad.2013.01.038
  13. Burdick KE, 2014, PSYCHOL MED, V44, P3083, DOI 10.1017/S0033291714000439
  14. Chakrabarty T, 2021, ACTA PSYCHIAT SCAND, V143, P151, DOI 10.1111/acps.13245
  15. Cutler R., 2011, WORLDWIDE CLIN TRIAL
  16. Das TK, 2019, PROG NEURO-PSYCHOPH, V91, P94, DOI 10.1016/j.pnpbp.2018.08.006
  17. Hermiller MS, 2019, HIPPOCAMPUS, V29, P595, DOI 10.1002/hipo.23054
  18. Hernaus D, 2017, EUR NEUROPSYCHOPHARM, V27, P399, DOI 10.1016/j.euroneuro.2017.02.004
  19. Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
  20. Holiga S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206583
  21. Howarth C, 2021, PHILOS T R SOC B, V376, DOI 10.1098/rstb.2019.0630
  22. Iwabuchi SJ, 2015, NEUROSCI BIOBEHAV R, V51, P77, DOI 10.1016/j.neubiorev.2015.01.006
  23. Jensen JH, 2016, J AFFECT DISORDERS, V205, P378, DOI 10.1016/j.jad.2016.08.018
  24. Jiang J, 2017, J PSYCHIATR NEUROSCI, V42, P150, DOI 10.1503/jpn.150341
  25. Jolles DD, 2010, NEUROIMAGE, V52, P658, DOI 10.1016/j.neuroimage.2010.04.028
  26. Karantonis JA, 2021, SCHIZOPHRENIA BULL, V47, P1557, DOI 10.1093/schbul/sbab054
  27. Karantonis JA, 2021, J AFFECT DISORDERS, V281, P776, DOI 10.1016/j.jad.2020.11.064
  28. Laura D, 2018, NEURAL PLAST, V2018, DOI 10.1155/2018/3419871
  29. Liang SG, 2019, NEUROSCI BULL, V35, P867, DOI 10.1007/s12264-019-00381-w
  30. Macoveanu J, 2021, ACTA PSYCHIAT SCAND, V144, P379, DOI [10.1016/j.euroneuro.2021.10.264, 10.1111/acps.13349]
  31. Macoveanu J, 2018, J PSYCHOPHARMACOL, V32, P1075, DOI 10.1177/0269881118783334
  32. Magalona SC, 2013, CNS DRUGS, V27, P663, DOI 10.1007/s40263-013-0082-x
  33. Millan MJ, 2012, NAT REV DRUG DISCOV, V11, P141, DOI 10.1038/nrd3628
  34. Miskowiak KW, 2017, BIPOLAR DISORD, V19, P614, DOI 10.1111/bdi.12534
  35. Miskowiak KW, 2016, ACTA PSYCHIAT SCAND, V134, P249, DOI 10.1111/acps.12597
  36. Miskowiak KW, 2016, PSYCHOL MED, V46, P1679, DOI 10.1017/S0033291716000209
  37. Miskowiak KW, 2019, CNS SPECTRUMS, V24, P30, DOI 10.1017/S1092852918001062
  38. Miskowiak KW, 2015, BIOL PSYCHIAT, V78, P270, DOI 10.1016/j.biopsych.2014.12.013
  39. Miskowiak KW, 2014, J CLIN PSYCHIAT, V75, P1347, DOI 10.4088/JCP.13m08839
  40. Moher D, 2016, REV ESP NUTR HUM DIE, V20, P148, DOI 10.14306/renhyd.20.2.223
  41. Mothersill D, 2019, BIOL PSYCHIAT-COGN N, V4, P688, DOI 10.1016/j.bpsc.2019.03.005
  42. Nathan PJ, 2014, CURR OPIN PHARMACOL, V14, P54, DOI 10.1016/j.coph.2013.11.009
  43. NIH National Heart Lung and Blood Institute, HLTH TOP STUD QUAL A
  44. Ott CV, 2021, NEUROPSYCHOPHARMACOL, V46, P1113, DOI 10.1038/s41386-020-00901-7
  45. Ott CV, 2021, BIPOLAR DISORD, V23, P487, DOI 10.1111/bdi.13021
  46. Ott CV, 2019, EUR NEUROPSYCHOPHARM, V29, P319, DOI 10.1016/j.euroneuro.2019.01.105
  47. Ott CV., 2020, NEUROPSYCHOPHARMACOL, V40, pS412
  48. Petersen CS, 2021, CNS SPECTRUMS, V26, P333, DOI 10.1017/S1092852920000061
  49. Plichta MM, 2012, NEUROIMAGE, V60, P1746, DOI 10.1016/j.neuroimage.2012.01.129
  50. Poldrack RA, 2008, NEUROIMAGE, V40, P409, DOI 10.1016/j.neuroimage.2007.11.048
  51. Price CJ, 1999, HUM BRAIN MAPP, V8, P102, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<102::AID-HBM6>3.0.CO;2-J
  52. Pu SH, 2018, PSYCHOL MED, V48, P2717, DOI 10.1017/S003329171800034X
  53. Ramsay IS, 2015, SCHIZOPHRENIA BULL, V41, P1276, DOI 10.1093/schbul/sbv025
  54. Rodriguez P, 2016, RADIOLOGY, V281, P516, DOI 10.1148/radiol.2016152893
  55. Rose EJ, 2006, PSYCHOPHARMACOLOGY, V185, P339, DOI 10.1007/s00213-006-0334-2
  56. Schmidt A, 2014, PSYCHOPHARMACOLOGY, V231, P3879, DOI 10.1007/s00213-014-3526-1
  57. Sherwood MS, 2019, NEUROIMAGE, V195, P475, DOI 10.1016/j.neuroimage.2019.03.078
  58. Smith J, 2018, MOL PSYCHIATR, V23, P1127, DOI 10.1038/mp.2017.104
  59. Spurny B, 2021, NEUROIMAGE, V232, DOI 10.1016/j.neuroimage.2021.117913
  60. Takeuchi H, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00681
  61. Takeuchi H, 2011, J NEUROSCI, V31, P12139, DOI 10.1523/JNEUROSCI.2948-11.2011
  62. Van Rheenen T E, 2017, Psychol Med, V47, P1848, DOI 10.1017/S0033291717000307
  63. van Ruitenbeek P, 2013, BRIT J PHARMACOL, V170, P144, DOI 10.1111/bph.12184
  64. van Ruitenbeek P, 2018, HUM PSYCHOPHARM CLIN, V33, DOI 10.1002/hup.2675
  65. Van Snellenberg JX, 2006, NEUROPSYCHOLOGY, V20, P497, DOI 10.1037/0894-4105.20.5.497
  66. Wang WN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08944-5
  67. Watson S, 2012, BIOL PSYCHIAT, V72, P943, DOI 10.1016/j.biopsych.2012.05.029
  68. Xie Q, 2012, PSYCHOPHARMACOLOGY, V223, P417, DOI 10.1007/s00213-012-2730-0
  69. Yalin N, 2021, PSYCHONEUROENDOCRINO, V125, DOI 10.1016/j.psyneuen.2020.105116
  70. Zandbelt BB, 2008, NEUROIMAGE, V42, P196, DOI 10.1016/j.neuroimage.2008.04.183
  71. Petersen JZ, 2022, BIPOLAR DISORD, V24, P69, DOI 10.1111/bdi.13100
  72. Zhang QS, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00244

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - LIM/21